Different arms of the adaptive immune system induced by a combination vaccine work in concert to provide enhanced clearance of influenza

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Cobbin, Joanna C A ^a   Zeng, Weiguang ^a   Jackson, David C ^a   Brown, Lorena E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; TOLL LIKE RECEPTOR 2; LIPOPEPTIDE; S-(2,3-BIS(PALMITOYLOXY)PROPYL)CYSTEINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; INFLUENZA A; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ULTRAFILTRATION; VIRAL CLEARANCE; VIRUS NEUTRALIZATION; VIRUS TITRATION; ANIMAL; BAGG ALBINO MOUSE; DOG; IMMUNOLOGY; INFLUENZA A VIRUS; MDCK CELL LINE; ORTHOMYXOVIRIDAE INFECTIONS; VIRUS LOAD;

MUS; ORTHOMYXOVIRIDAE;

ADAPTIVE IMMUNITY; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DOGS; INFLUENZA A VIRUS; INFLUENZA VACCINES; LIPOPEPTIDES; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VIRAL LOAD;

EID: 84919341596     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115356     Document Type: Article

References (38)

1. Osterholm M, Kelley NS, Manske JM, Ballering KS, Leighton TR, et al. (October 2012) The compelling need for game-changing influenza vaccines: An analysis of the influenza vaccine enterprise and recommendations for the future. Comprehensive Influenza Vaccine Initiative (CCIVI), Center for Infectious Disease Research & Policy. Available: http://www.cidrap.umn.edu/cidrap/files/80/ccivi report.pdf. Accessed 2014 December 1.
2. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases 12: 36-44.
3. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, et al. (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13: 1399-1402.
4. Fiers W, Neirynck S, Deroo T, Saelens X, Vanlandschoot P, et al. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nature Medicine 5: 1157-1163.
5. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, et al. (2003) Induction of influenza type A virusspecific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21: 2616-2626.
6. Pejoski D, Zeng W, Rockman S, Brown LE, Jackson DC (2010) A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody. Immunology and Cell Biology 88: 605-611.
7. Ekiert DC, Bhabha G, Elsliger M-A, Friesen RHE, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
8. Wang TT, Tan GS, Hai R, Pica N, Ngai L, et al. (2010) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proceedings of the National Academy of Sciences of the United States of America 107: 18979-18984.
9. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, et al. (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1: e00018-00010.
10. Wei C-J, Boyington JC, McTamney PM, Kong W-P, Pearce MB, et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064.
11. Deliyannis G, Jackson DC, Ede NJ, Zeng W, Hourdakis I, et al. (2002) Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. Journal of Virology 76: 4212-4221.
12. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, et al. (2004) A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proceedings of the National Academy of Sciences of the United States of America 101: 15440-15445.
13. Tan ACL, Eriksson EMY, Kedzierska K, Deliyannis G, Valkenburg SA, et al. (2012) Polyfunctional CD8(+) Tcells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope. Antiviral Research 94: 168-178.
14. Baz M, Samant M, Zekki H, Tribout-Jover P, Plante M, et al. (2012) Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clinical and Vaccine Immunology 19: 209-218.
15. McMichael AJ, Gotch F, Cullen P, Askonas B, Webster RG (1981) The human cytotoxic T cell response to influenza A vaccination. Clinical and Experimental Immunology 43: 276-284.
16. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, et al. (2013) Cellular immune correlates of protection against symptomatic pandemic influenza. Nature Medicine 19: 1305-1312.
17. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, et al. (2012) Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clinical Infectious Diseases 55: 19-25.
18. Deliyannis G, Kedzierska K, Lau YF, Zeng W, Turner SJ, et al. (2006) Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. European Journal of Immunology 36: 770-778.
19. Lau YF, Deliyannis G, Zeng W, Mansell A, Jackson DC, et al. (2006) Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. International Immunology 18: 1801-1813.
20. Ng WC, Gilbertson B, Lim B, Zeng W, Jackson DC, et al. (2009) Lipopeptide vaccines illustrate the potential role of subtype-crossreactive T cells in the control of highly virulent influenza. Influenza and Other Respiratory Viruses 3: 177-182.
21. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, et al. (2013) Cross-reactive influenzaspecific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. Journal of Immunology 190: 1837-1848.
22. DiLillo DJ, Tan GS, Palese P, Ravetch JV (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nature Medicine 20: 143-151.
23. Harling-McNabb L, Deliyannis G, Jackson DC, Gerondakis S, Grigoriadis G, et al. (1999) Mice lacking the transcription factor subunit Rel can clear an influenza infection and have functional anti-viral cytotoxic T cells but do not develop an optimal antibody response. International Immunology 11: 1431-1439.
24. Tannock GA, Paul JA, Barry RD (1984) Relative immunogenicity of the cold-adapted influenza virus A/ Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infection and Immunity 43: 457-462.
25. Zeng W, Ghosh S, Lau YF, Brown LE, Jackson DC (2002) Highly immunogenic and totally synthetic lipopeptides as self-adjuvanting immunocontraceptive vaccines. Journal of Immunology 169: 4905-4912.
26. Jackson DC, Drummer HE, Brown LE (1994) Conserved determinants for CD4+ T cells within the light chain of the H3 hemagglutinin molecule of influenza virus. Virology 198: 613-623.
27. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, et al. (1986) The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 44: 959-968.
28. Jackson DC, Tang XL, Brown LE, Murray JM, White DO, et al. (1986) Antigenic determinants of influenza virus hemagglutinin. XII. the epitopes of a synthetic peptide representing the C-terminus of HA1. Virology 155: 625-632.
29. Kendal AP, Pereira PM, Skehel JJ (1982) Concepts and procedures for laboratory-based influenza surveillance. Atlanta, GA: US Department of Health and Human Services, CDC.
30. Brown LE, Jackson DC (2005) Lipid-based self-adjuvanting vaccines. Current Drug Delivery 2: 383-393.
31. Zeng W, Eriksson EM, Lew A, Jackson DC (2011) Lipidation of intact proteins produces highly immunogenic vaccine candidates. Molecular Immunology 48: 490-496.
32. Chua BY, Pejoski D, Turner SJ, Zeng W, Jackson DC (2011) Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2. Journal of Immunology 187: 1692-1701.
33. Middleton D, Rockman S, Pearse M, Barr I, Lowther S, et al. (2009) Evaluation of Vaccines for H5N1 Influenza Virus in Ferrets Reveals the Potential for Protective Single-Shot Immunization. Journal of Virology 83: 7770-7778.
34. Robertson JS, Nicolson C, Harvey R, Johnson R, Major D, et al. (2011) The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 29: 1836-1843.
35. Uyeki TM, Cox NJ (2013) Global concerns regarding novel influenza A (H7N9) virus infections. The New England Journal of Medicine 368: 1862-1864.
36. Osterholm MT, Ballering KS, Kelley NS (2013) Major Challenges in Providing an Effective and Timely Pandemic Vaccine for Influenza A(H7N9). Journal of the American Medical Association: 1-2.
37. Bodmer HC, Pemberton RM, Rothbard JB, Askonas BA (1988) Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein. Cell 52: 253-258.
38. Sherman LA, Burke TA, Biggs JA (1992) Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. The Journal of Experimental Medicine 175: 1221-1226.